ClinicalTrials.gg
CompletedNCT04360434Updated Nov 3, 2023

First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy

A Phase 1 interventional study of NI006 and Placebo in Amyloid Transthyretin Cardiomyopathy, sponsored by Neurimmune AG. Completed at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by Neurimmune AG · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Amyloidosis with a site in France — 17 open to participants now, 22 under way, 8 of them phase 3. Amyloidosis · France.

Enrollment
36th of 48
46 · median 145
Started
2020
with 5 others
Phase 1
4 of 56
1 open now
Registered
31st of 56
by date
Lead sponsor
2 of 56
Neurimmune AG

Among the 56 studies in Amyloidosis with a site in France, this one is the 36th largest by enrollment of the 48 interventional ones that give a count, is one of 6 that started in 2020, is one of 4 in phase 1, and was the 31st registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

17 of the 56 studies in Amyloidosis with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Amyloidosis with a site in France, or all of them as a file.
02

Study summary

A phase 1, randomized, placebo-controlled, double-blind, dose escalation trial combining single-ascending dose and multiple-ascending dose phases of NI006 or placebo, followed by an open-label extension phase in subjects with Amyloid Transthyretin Cardiomyopathy (ATTR-CM).

Read the detailed description

This phase 1, randomized, placebo-controlled, double-blind trial in subjects with Amyloid Transthyretin Cardiomyopathy (ATTR-CM) consists of single-ascending dose (SAD) and multiple-ascending dose (MAD) phases, followed by an open-label extension (OLE) phase.

In the SAD phase subjects are randomized in a 4:2 ratio to receive a single infusion of NI006 or placebo.

Subjects completing the SAD phase will be enrolled in the MAD phase upon evaluation of all available safety data and receive a maximum of 3 additional infusions of NI006 or placebo every 28 days.

Subjects completing the MAD phase will have the possibility to continue in an OLE phase with treatment up-titrations and switch from placebo to NI006 and receive up to 8 infusions of NI006 every 28 days.

Subjects of cohort 1 to 5 who received at least one dose of NI006 during the OLE phase will have the possibility for a second OLE phase (OLE2) after completing the OLE phase and receive up to 10 additional infusions of NI006 every 28 days.

In total, about 42 subjects are planned to be enrolled in 7 cohorts of 6 subjects each, at 6 ascending dose levels.

03

Conditions studied

  • Amyloid Transthyretin Cardiomyopathy

Keywords

  • ATTR
  • Transthyretin
  • Amyloidosis
  • Cardiomyopathy
  • ATTR-CM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained from the subject prior to any trial-related procedure indicating that he/she understands the purpose of, and procedures required for the trial and is willing to participate in it
  2. Male or female subjects aged ≥18 years (and \< 85 years only for cohort 7) at the time of obtaining informed consent and with confirmed availability for the scheduled trial visits
  3. Confirmed ATTR-Cardiomyopathy diagnosis established by:

    • Polarizing light microscopy of green birefringent material in Congo red-stained tissue specimens and confirmed diagnosis of ATTR amyloidosis by IHC or mass spectrometry OR
    • positive bone scintigraphy using either DPD, HMDP or PYP, with cardiac signal intensity indicative of ATTR-Cardiomyopathy (early phase imaging: cardiac mediastinum ratio > 1.21; late phase imaging: Perugini Grade 2 or 3) and absence of gammopathy (negative serum and urine immunofixation electrophoresis plus normal free light chain serum ratio). If a gammopathy is detected, diagnosis must be established based on tissue as indicated above
  4. Known genotype as follows:

    1. Known pathogenic TTR mutation for subjects with hereditary ATTR- Cardiomyopathy
    2. Known negative genetic testing for a TTR mutation for subjects with sporadic, WT- ATTR-Cardiomyopathy
  5. Chronic Heart Failure with all of the following characteristics:

    1. ≥40%
    2. LVWT ≥14 mm, measured by echocardiography
    3. NT-proBNP level ≥600 pg/mL
    4. Able to walk ≥150 meter in the 6-MWT
    5. class III (applicable only for cohort 7)
    6. No hospitalizations for cardiac disease for at least 30 calendar days prior to screening
  6. General health status acceptable for a participation in a clinical trial with a Performance Status ≥60%
  7. Stable pharmacological treatment of any other chronic condition for at least 30 calendar days prior to screening, with the exclusion of immunomodulatory and treatments
  8. ≥1000 cells/mm³, count ≥100,000 cells/mm³, and ≥10 g/dL
  9. Women of must have a negative serum pregnancy test at screening and must agree to use highly effective physician-approved from screening to 5 months after ending trial participation
  10. Males must be surgically sterile or must agree to use highly effective physician-approved contraception throughout of the trial participation, and for 5 months after ending trial participation

Exclusion criteria

Exclusion Criteria:

  1. Amyloid light-chain amyloidosis or any other non ATTR amyloidosis
  2. Heart failure corresponding to class IV
  3. Uncontrolled hypertension with systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg confirmed by 3 measurements in supine position recorded with 5 minutes break in between the measurements
  4. Hypotension with systolic pressure ≤ 90 mmHg or diastolic pressure ≤ 60 mmHg confirmed by 3 measurements in supine position recorded with 5 minutes break in between the measurements
  5. NT-proBNP ≥6'000 pg/mL (NT-proBNP ≥8'500 pg/mL applicable only for cohort 7)
  6. Heart failure not predominantly caused by ATTR-Cardiomyopathy
  7. Any severe uncorrected valve disease
  8. Chronic liver disease with liver function test abnormalities:

    1. and AST > 2.5 ×
    2. Total > 2 × ULN
  9. Respiratory insufficiency requiring oxygen therapy
  10. Renal insufficiency with \< 30 mL/min/1.73 m2 using the CKD-EPI equation
  11. Active with exception of the following:

    1. Adequately treated basal cell carcinoma
    2. Squamous cell carcinoma of the skin
    3. In situ cervical cancer
    4. Low risk prostate cancer with Gleason score \< 7 and prostate specific antigen \< 10 mg/mL
    5. Any other cancer from which the subject has been disease-free for ≥ 2 years
  12. Uncontrolled infection as per Investigator's judgement
  13. Known infection, seropositivity for HIV, and C as well as active hepatitis A
  14. disease requiring /modulating treatment in the last 2 years
  15. History of organ transplantation or ventricular assist device
  16. Polyneuropathy disability score > IIIA
  17. Suspected or known intolerance/allergy to proteins or any components of the medicinal product
  18. Concomitant immunosuppressant therapy e.g., , prednisone, dexamethasone except as indicated in low dose (i.e., up to 10 mg prednisone or equivalent daily is allowed) for other medical conditions such as inhaled steroid for asthma
  19. Use of the following drugs acting on TTR or ATTR: tolcapone, diflunisal, patisiran, inotersen, and long-term doxycycline, in the 30 calendar days prior to signing form. Tafamidis is permitted if it is given as standard of care in a stable dose for at least 30 calendar days prior to signing the informed consent form
  20. Participation in another investigational clinical trial or intake of investigational drug within 30 calendar days before signing the informed consent form
  21. Suspected or known drug or alcohol abuse
  22. Serious psychiatric or any other medical condition (including laboratory abnormalities), which, in the opinion of the Investigator, makes the subject unsuitable for inclusion and puts the subject at an unacceptable risk
  23. Subject is nursing or is considering becoming pregnant during the trial or in the 5 months after ending trial participation
  24. Unwillingness or inability to adhere to the trial requirements
  25. If subject is in any way dependent on Neurimmune AG or the principal Investigator or if the subject is accommodated in an establishment on judicial or administrative order
  26. Employee or immediate family (spouse, parent, child or sibling, whether biological or legally adopted) of an employee of Neurimmune AG, the contract research organization or the trial site
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    NI006

    Dose escalation in up to 6 dose cohorts. Subjects will be administered a single dose of NI006 in the SAD, multiple doses of NI006 in the MAD and OLE phases.

    Drug: NI006

  • Placebo comparator
    Placebo

    Subjects will be administered a single dose of placebo in the SAD phase and multiple doses of placebo in the MAD phase. In the OLE phase, all subjects will be administered multiple doses of NI006.

    Drug: Placebo

Interventions

  • DrugNI006

    NI006 will be administered intravenously

  • DrugPlacebo

    Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously

06

What researchers measure

Primary outcomes

  1. Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters, vital signs, electrocardiogram and echocardiogram

    Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters (hematology, clinical chemistry, immunology, urinalysis), vital signs, electrocardiogram and echocardiogram

    Time frame: 4 months

  2. Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters, vital signs, electrocardiogram and echocardiogram

    Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters (hematology, clinical chemistry, immunology, urinalysis), vital signs, electrocardiogram and echocardiogram

    Time frame: 12 months

  3. Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters, vital signs, electrocardiogram and echocardiogram

    Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters (hematology, clinical chemistry, immunology, urinalysis), vital signs, electrocardiogram and echocardiogram

    Time frame: additional up to 10 months

Secondary outcomes

  1. NI006 pharmacokinetic profile and parameters - Cmax

    Maximum observed serum concentration (Cmax) of NI006

    Time frame: 4 months

  2. NI006 pharmacokinetic profile and parameters - Tmax

    Time to maximum observed serum concentration (Tmax) of NI006

    Time frame: 4 months

  3. NI006 pharmacokinetic profile and parameters - AUCinf

    Area under the serum concentration-time curve from zero to infinity (AUCinf) of NI006

    Time frame: 1 month

  4. NI006 pharmacokinetic profile and parameters - CL

    Serum clearance (CL) of NI006

    Time frame: 4 months

  5. NI006 pharmacokinetic profile and parameters - Vz

    NI006 apparent volume of distribution during terminal phase (Vz)

    Time frame: 4 months

  6. NI006 pharmacokinetic profile and parameters - Vss

    NI006 apparent volume of distribution at steady state (Vss)

    Time frame: 4 months

  7. NI006 pharmacokinetic profile and parameters - t½

    Terminal elimination half-life (t½) of NI006 in serum

    Time frame: 4 months

  8. NI006 pharmacokinetic profile and parameters - AUCtau

    Area under the serum concentration-time curve from time zero to the end of the dosing interval after the first dose (AUCtau) of NI006

    Time frame: 4 months

  9. NI006 pharmacokinetic profile and parameters - RaccCmax

    Accumulation ratio for maximum concentration (RaccCmax) of NI006 in serum

    Time frame: 4 months

  10. NI006 pharmacokinetic profile and parameters - RaccAUC

    Accumulation ratio calculated from AUC (RaccAUC) of NI006 in serum

    Time frame: 4 months

  11. NI006 pharmacokinetic profile and parameters - Ctrough

    Minimum observed concentration (Ctrough) of NI006 in serum

    Time frame: 12 months

  12. NI006 OLE2 pharmacokinetic profile and parameters - Ctrough

    Minimum observed concentration (Ctrough) of NI006 in serum

    Time frame: up to 10 months

  13. NI006 pharmacokinetic profile and parameters - dose-normalized Ctrough

    Dose-normalized minimum observed concentration (Ctrough) of NI006 in serum

    Time frame: 12 months

  14. NI006 OLE2 pharmacokinetic profile and parameters - dose-normalized Ctrough

    Dose-normalized minimum observed concentration (Ctrough) of NI006 in serum

    Time frame: up to 10 months

Other outcomes

  1. Exploratory - Efficacy of multiple doses of NI006 on 6-Minute Walk Test (6-MWT)

    Changes in 6-MWT

    Time frame: 4 and 12 months

  2. Exploratory - Efficacy of multiple doses of NI006 on patient questionnaire outcome

    Changes in patient questionnaire outcome

    Time frame: 4 and 12 months

  3. Exploratory - Efficacy of multiple doses of NI006 on amyloid load

    Changes in amyloid load assessed by cardiac imaging

    Time frame: 4 and 12 months

  4. Exploratory - Efficacy of multiple doses of NI006 on cardiac biomarkers - NT-proBNP

    Changes in NT-proBNP concentration

    Time frame: 4 and 12 months

  5. Exploratory - Efficacy of multiple doses of NI006 on cardiac biomarkers - Troponin-T

    Changes in Troponin-T concentration

    Time frame: 4 and 12 months

  6. Exploratory - Immunogenicity of NI006

    Determination of anti-drug antibody response

    Time frame: 4 and 12 months

07

Study locations

6 sites
  • Hôpital Henri Mondor
    Créteil, 94000, France
  • CHU de Rennes - Hôpital Pontchaillou
    Rennes, 35033, France
  • CHU Toulouse - Hôpital Rangueil
    Toulouse, 31059, France
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • University Medical Center Groningen
    Groningen, 9713, Netherlands
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, 28222, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Jul 2023, 41 months.

Of 18 phase 1 interventional studies under Amyloidosis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 58. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2020
First posted
Apr 24, 2020
StartActual
Feb 10, 2020
Primary completionActual
Jul 26, 2023
CompletionActual
Jul 26, 2023
Last update
Nov 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04360434
Lead sponsor
Neurimmune AG
Responsible party
Sponsor
First posted
Apr 24, 2020
Start date
Feb 10, 2020
Primary completion
Jul 26, 2023
Completion
Jul 26, 2023
Last update
Nov 3, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cliramitug

Start the discussion